SCHEMBL6085707

SCHEMBL6085707

O=C(Nc1cccc(-c2n[nH]cc2-c2nc3cc4ccccc4cc3o2)c1)c1cc(Cl)nc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TP53 P04637 7/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 11/20 0.45
RXFP1 Q9HBX9 2/20 0.45
KDM4E B2RXH2 2/20 0.44
POLB P06746 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
THRB P10828 1/20 0.43
AGPAT2 O15120 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085202 0.91 MAPT (0.48) TP53MAPTRXFP1KDM4EPOLB
SCHEMBL6085923 0.86 TP53 (0.47) TP53LMNAMAPTKDM4EPOLB
SCHEMBL6085686 0.85 TP53 (0.53) TP53MAPTKDM4ESMN1; SMN2MEN1
SCHEMBL6085271 0.83 MAPT (0.46) TP53LMNAMAPTRXFP1KDM4E
SCHEMBL6084227 0.82 TP53 (0.49) TP53MAPTRXFP1KDM4EPOLB
SCHEMBL6084969 0.81 LMNA (0.64) TP53LMNAMAPTRXFP1KDM4E
SCHEMBL6084151 0.81 MAPT (0.61) TP53LMNAMAPTRXFP1KDM4E
SCHEMBL6083942 0.81 P2RY14 (0.54) TP53MAPTKDM4EPOLBALDH1A1
SCHEMBL6085449 0.80 TP53 (0.59) TP53MAPTRXFP1KDM4EPOLB
SCHEMBL6222058 0.80 HSD17B10 (0.47) TP53MAPTKDM4EPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP disclosed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 TP53 466/4885LMNA 4688/4885MAPT 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.